Advertisement


Rami Manochakian, MD, FASCO, on Tarlatamab vs Chemotherapy for Second-Line Treatment of SCLC: Expert Point of View

2025 ASCO Annual Meeting

Advertisement

Rami Manochakian, MD, FASCO, of Mayo Clinic Florida, offers his thoughts on findings from the primary analysis of the phase III DeLLphi-304 trial, which compared tarlatamab-dlle, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, with chemotherapy as a second-line treatment of patients with small cell lung cancer (SCLC) (LBA8008). 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
DELPHI-304 trial is a randomized controlled phase 3 trial comparing tarlatamab to chemotherapy in the second-line treatment of patients with small cell lung cancer who had disease progression after first-line chemotherapy, with or without a checkpoint inhibitor. Tarlatamab is a bispecific T-cell engager that targets DLL3 and CD3 and was approved in the second-line treatment and beyond of advanced small cell lung cancer based on DELPHI-301, which showed a very good response rate. DELPHI-304, of which the results were reported by the investigators at the ASCO 2025 Annual Meeting, also had an associated manuscript published in the New England Journal of Medicine. The study showed impressive, significant improvement in overall survival—statistically significant and, more importantly, meaningful clinical improvements. The hazard ratio was 0.6. There was a median overall survival improvement of more than five months, from 8.3 to 11.6 months. Other clinical outcomes that were reported included a response rate of about 35%. There was also improvement in progression-free survival. Kudos also to the investigators who reported patient outcomes, and there was a significant improvement in patient symptoms, particularly dyspnea and cough, with tarlatamab. When it comes to safety profile, tarlatamab had overall a better safety profile. There were significantly fewer grade 3 or above adverse events compared to chemotherapy. When it comes to the unique side effects—CRS (cytokine release syndrome) and ICANS—they were mostly grade 1 or 2 and managed fairly well with minimal issues, except maybe one case of ICANS. Why is this study important? Very important, because it's the first study ever to show a drug that has a better overall survival benefit compared to chemotherapy in the second-line setting treatment of small cell lung cancer. This is a standard-of-care treatment. From now on, if not already, I will be using it in clinic. I'm already using it. A couple of things to make sure we address on this drug, tarlatamab. We do know that there are some logistics to administering the drug—maybe in the hospital for the first couple of doses, as was done initially in the trial, and then it was adjusted. The reason is to watch for those side effects. Although they're rare—the reactions, the CRS—it requires some extra time of observation after the infusion. But I think as we evolve, we're seeing that has been more doable, and the study itself showed that actually observing in outpatient is doable. And then of course, more importantly, even though the percentage of higher-grade adverse events was lower with tarlatamab, we still owe it to our patients to monitor closely, to optimize and do everything to support them, and to treat those in a timely manner.

Related Videos

Hematologic Malignancies

Andrew Kuykendall, MD, on Hepcidin Mimetic for Polycythemia Vera

Andrew Kuykendall, MD, of Moffitt Cancer Center, discusses findings from the phase III VERIFY trial, which compared the efficacy of rusfertide vs placebo in patients with polycythemia vera who continue their current standard of care therapy (Abstract LBA3). 

Breast Cancer
Issues in Oncology

Neil M. Iyengar, MD, on Cancer Risk Reduction: Effects of Menopausal HRT and GLP-1 RAs

Neil M. Iyengar, MD, of Memorial Sloan Kettering Cancer Center, reviews several studies that aimed to answer two questions: does menopausal hormone therapy (HRT) impact overall survival and breast cancer–specific mortality in younger women diagnosed with high-risk disease (Abstract 10506); and do GLP-1 receptor agonists (GLP-1 RAs), a class of weight-loss medications, have cancer risk reduction properties (Abstracts 10507 and 10508). 

Breast Cancer

Hope S. Rugo, MD, FASCO, and Rebecca Alexandra Dent, MD, FASCO, on Breast Cancer Data Highlights: Sequencing of Endocrine Therapy

Hope S. Rugo, MD, FASCO, of City of Hope, and Rebecca Alexandra Dent, MD, FASCO, of National Cancer Centre Singapore, review the results of a biomarker analysis of the DESTINY-Breast06 trial, which evaluated trastuzumab deruxtecan after endocrine therapy in patients with metastatic breast cancer (Abstract 1013). They also discuss findings from the SERENA-6 and EMBER-3 trials, also presented at ASCO 2025, and what all this new data means for the sequencing of endocrine therapy in patients with breast cancer. 

Prostate Cancer

Nicholas D. James, PhD, FRCP, MBBS, on Using AI to Identify Benefit From Prostate Cancer Therapy

Nicholas D. James, PhD, FRCP, MBBS, of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, describes the use of a multimodal artificial intelligence (AI) model to identify benefit from second-generation androgen receptor pathway inhibitors in patients with high-risk nonmetastatic prostate cancer participating in the STAMPEDE trial (Abstract 5001). 

 

Leukemia

Nitin Jain, MD, on Front-Line Therapies for CLL: Research Highlights From ASCO 2025

Nitin Jain, MD, Professor in the Department of Leukemia and Director of the Leukemia CAR-T Program at The University of Texas MD Anderson Cancer Center, shares his expert point of view on data presented on front-line therapies for chronic lymphocytic leukemia (CLL) presented at the 2025 ASCO Annual Meeting. 

Advertisement

Advertisement




Advertisement